Clinical and molecular characteristics of acute myeloid leukemia and the dismal prognosis of TP53 mutations in a real-world setting

References

• Hwang SM. Classification of acute myeloid leukemia. Blood Res. 2020;55(S1):S1–S4.
   PubMedGoogle Scholar
• Chebly A, Djambas Khayat C, Yammine T, et al. Pediatric M5 acute myeloid leukemia with MLL-SEPT6 fusion and a favorable outcome. Leuk Res Rep. 2021;16:100277.
   PubMedGoogle Scholar
• Liu G, Liu L, Bartolo DD, et al. Acute promyelocytic leukemia with rare genetic aberrations: a report of three cases. Genes(Basel). 2022;14(1):46.
   Google Scholar
• Chebly A, Haddad FG, Bassil J, et al. A rare case of acute myeloid leukemia with t(12;19)(q13;q13). Leuk Res Rep. 2020;14:100216.
   PubMedGoogle Scholar
• Milczarek S, Studniak E, Baumert B, et al. Case of patient with AML with complex karyotype including ultra-rare t(4;8)(q32;q13), t(4;11)(q21;p15) and familial aggregation of myeloid malignancies. Medicina (Kaunas). 2022;58(1):105.
   PubMed Web of Science ®Google Scholar
• Creutzig U, Zimmermann M, Reinhardt D, et al. Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups. Cancer. 2016;122(24):3821–3830.
   PubMed Web of Science ®Google Scholar
• Bolouri H, Farrar JE, Triche T Jr, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specifific mutational interactions. Nat Med. 2017;24(1):103–112.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classifification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221.
   PubMed Web of Science ®Google Scholar
• Kastenhuber ER, Lowe SW. Putting p53 in context. Cell. 2017;170(6):1062–1078.
   PubMed Web of Science ®Google Scholar
• Bykov VJN, Eriksson SE, Bianchi J, et al. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 2018;18(2):89–102.
   PubMed Web of Science ®Google Scholar
• Prokocimer M, Molchadsky A, Rotter V. Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy. Blood. 2017;130(6):699–712.
   PubMed Web of Science ®Google Scholar
• Kuykendall A, Duployez N, Boissel N, et al. Acute myeloid leukemia: the good, the bad, and the ugly. Am Soc Clin Oncol Educ Book. 2018;38:555–573.
   PubMedGoogle Scholar
• Niparuck P, Police P, Noikongdee P, et al. TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Diagn Pathol. 2021;16(1):1–8.
   PubMed Web of Science ®Google Scholar
• Short NJ, Montalban-Bravo G, Hwang H, et al. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv. 2020;4(22):5681–5689.
   PubMed Web of Science ®Google Scholar
• Alwash Y, Khoury JD, Tashakori M, et al. Development of TP53 mutations over the course of therapy for acute myeloid leukemia. Am J Hematol. 2021;96(11):1420–1428.
   PubMed Web of Science ®Google Scholar
• Li Y, Wan H, Jing Y. Molecular characterization and clinical treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients with TP53 mutation. Cl Lymph Myelom Leuk. 2021;21(12):841–851.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Cazzola A, Schlegel C, Jansen I, et al. TP53 deficiency permits chromosome abnormalities and karyotype heterogeneity in acute myeloid leukemia. Leukemia. 2019;33(11):2619–2627.
   PubMed Web of Science ®Google Scholar
• Rücker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012;119(9):2114–2121.
   PubMed Web of Science ®Google Scholar
• Stengel A, Kern W, Haferlach T, et al. The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases. Leukemia. 2017;31(3):705–711.
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Chilkulwar A, Saliba RM, et al. Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations. Blood. 2018;131(26):2989–2992.
   PubMed Web of Science ®Google Scholar
• Hou HA, Chou WC, Kuo YY, et al. TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution. Blood Cancer J. 2015;5(7):E331–E331.
   PubMedGoogle Scholar
• Kadia TM, Jain P, Ravandi F, et al. TP53 mutations in newly diagnosed acute myeloid leukemia: clinicomolecular characteristics, response to therapy, and outcomes. Cancer. 2016;122(22):3484–3491.
   PubMed Web of Science ®Google Scholar
• Goel S, Hall J, Pradhan K, et al. High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort. Leukemia. 2016;30(8):1793–1795.
   PubMed Web of Science ®Google Scholar
• Döhner H, Dolnik A, Tang L, et al. Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. Leukemia. 2018;32(12):2546–2557.
   PubMed Web of Science ®Google Scholar
• Grob T, Al Hinai ASA, Sanders MA, et al. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2022;139(15):2347–2354.
   PubMed Web of Science ®Google Scholar
• Granowicz EM, Jonas BA. Targeting TP53-mutated acute myeloid leukemia: research and clinical developments. Onco Targets Ther. 2022;15:423–436.
   PubMed Web of Science ®Google Scholar
• Molica M, Mazzone C, Niscola P, et al. TP53 mutations in acute myeloid leukemia: still a daunting challenge? Front Oncol. 2020;10:610820.
   PubMed Web of Science ®Google Scholar
• Klimovich B, Meyer L, Merle N. Partial p53 reactivation is sufficient to induce cancer regression. J Exp Clin Cancer Res. 2022;41(1):80.
   PubMed Web of Science ®Google Scholar